Porovnat metody

	Multicentrická randomizovaná klinická studie	Adaptivní randomizovaná klinická studie
Obor	Epidemiologie	Epidemiologie
Rodina	Process / pipeline	Process / pipeline
Rok vzniku	1970s–1980s (widespread adoption for large-scale efficacy trials)	Late 1990s–2000s (widespread adoption post-2010)
Tvůrce	Evolved from single-center RCT methodology; consolidated through landmark trials such as the MRC streptomycin trial (1948) and large cardiovascular mega-trials of the 1970s–1980s	Donald Berry and colleagues; formalized by FDA guidance in 2010 and 2019
Typ	Interventional experimental design	Experimental clinical trial design
Původní zdroj	Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185385	Berry, D. A. (2006). Bayesian clinical trials. Nature Reviews Drug Discovery, 5(1), 27–36.
Další názvy	multi-site RCT, multicenter RCT, multinational randomized trial, multicenter controlled trial	adaptive RCT, adaptive trial design, response-adaptive randomization trial, adaptive clinical trial
Příbuzné	6	6
Shrnutí	A multicenter randomized clinical trial (RCT) is an experimental study in which eligible participants are randomly assigned to intervention or control arms simultaneously across two or more clinical sites. By combining the rigor of randomization with enrollment from geographically or institutionally diverse centers, this design produces large samples and externally valid effect estimates that single-center trials rarely achieve. It is the regulatory gold standard for confirmatory efficacy and safety evaluation of new treatments.	An adaptive randomized clinical trial (adaptive RCT) is a prospective experimental study that uses pre-specified rules to modify one or more trial aspects — such as sample size, allocation ratios, or treatment arms — based on accumulating data collected during the trial itself, while maintaining statistical validity and integrity of the study.